Day: November 13, 2023

U.S. FDA granted Investigational Device Exemption (“IDE”) approval to initiate the BACKBEAT pivotal study evaluating AVIM therapy (BackBeat CNT) in hypertensive pacemaker patients BACKBEAT pivotal study on track to start enrollment before the end of 2023, with a mid-2025 target for completion of enrollment Expected operating cash runway sufficient into 2H 2026, beyond anticipated BACKBEAT top-line results readout, based on internal forecast FDA also granted conditional IDE approval for pivotal study of Virtue® SAB in coronary in-stent restenosis (“ISR”) patients; Virtue ISR-US study initiation targeted for 2024, pending Terumo partnership restructuringNEW HOPE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact...

Gevo to Host Conference Call Today at 4:30 p.m. ET ENGLEWOOD, Colo., Nov. 13, 2023 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”) today announced financial results for the third quarter of 2023 and recent corporate highlights. Recent Corporate HighlightsRenewable Natural Gas (“RNG”): The previously announced capacity expansion from 355,000 MMBtu to 400,000 MMBtu was completed during the third quarter of 2023.Verity: This quarter, we entered into agreements with an ethanol producer customer in the US Southwest. This brings our growing total ethanol producer customer base to three customers, and total planned volume of ethanol tracked by Verity to over 300M gallons per year, or approximately 2% of the US ethanol market, since March 2023. Our agreements with customers will allow them...

 — Closed on $3.2 Million Financing — Delivered $29.3 Million in nine-month revenue     — Won 2023 BeautyMatter NEXT Award — Named as finalist for 22nd annual Chicago Innovation Awards and 2024 Cosmetics & Toiletries Allē Awards  ROMEOVILLE, Ill., Nov. 13, 2023 (GLOBE NEWSWIRE) — Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that protect skin from environmental aggressors and aid in medical diagnostics — today announced financial results for the third quarter ended September 30, 2023.   Jess Jankowski, President and Chief Executive Officer, commented: “We’ve had our ups and downs in the third quarter, but critically, we’ve positioned ourselves for success as we look to a strong year for...

Advances rollout of POCare Platform and POCare Therapies GERMANTOWN, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) — Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the third quarter ended September 30, 2023. Vered Caplan, CEO of Orgenesis, said, “We continue to advance the commercial launch of our POCare Platform through Octomera, building out a decentralized network and infrastructure to deliver these advanced therapeutic services that are critically needed by the medical community. At the same time, we are focused on growing our POCare Network of hospitals and healthcare providers across the U.S., Europe, the Middle East and other regions, where advanced cell and gene therapies can be rapidly...

Selected Unaudited Financial Highlights for Q3 FY 2023 Self-mined Bitcoin revenue and Bitcoin mined increased 41% and 35% Q/Q, respectively, to $6.9 Million and 246 BTC Total Quarterly Revenue increased to $11.3 Million SG&A Expenses Decreased 42% Q/Q PITTSBURGH, Nov. 13, 2023 (GLOBE NEWSWIRE) — Mawson Infrastructure Group Inc. (NASDAQ: MIGI) (“Mawson”, Company), a digital infrastructure company, today announced its unaudited financial results and highlights for the third quarter ending September 30, 2023. Rahul Mewawalla, CEO and President of Mawson, said, “We are delighted to deliver a second successful consecutive quarter of significant double-digit sequential revenue growth for our self-mining business as we continued to execute our new operating excellence model combined with our business, technology, and financial optimization...

Strategic Focus On Cross-Platform Offerings and Brand Solutions Driving Improved Revenue Mix and 400bp Expansion in Gross Margins Year-over-Year as Company Progresses Toward Profitability LOS ANGELES, Nov. 13, 2023 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leading gaming media and entertainment company, today announced financial results for the three and nine months ended September 30, 2023 (“Q3 2023”). Q3 2023 Financial HighlightsRevenue of $45.6 million, a decrease of 10% compared to Q3 2022 Gross profit of $16.7 million, an increase of 1% compared to Q3 2022, with gross profit margins expanding 400 basis points year-over-year to 36.7% Operating expenses of $25.0 million, a decrease of 6% compared to Q3 2022 Ended the quarter with $2.8 million of cash, along with...

Phase 3 Adult Efficacy and Safety Trial Data Presented at Psych Congress Cingulate Closed a $4M Public Offering $5.8M of Debt Converted into CING Equity KANSAS CITY, Kan., Nov. 13, 2023 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING) (Cingulate or the Company), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today provided financial results for the quarter ended September 30, 2023, as well as a clinical and business update. Among other highlights, the Company announced data from its Phase 3 adult efficacy and safety trial, closed a $4 million public offering in September 2023 and converted of $5.8 million of debt into Cingulate equity in September 2023. “We are pleased...

Company to Host Webcast and Conference Call BRANFORD, Conn., Nov. 13, 2023 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) announced its financial results for the third quarter ended September 30, 2023. John Villano, CPA, Sachem Capital’s Chief Executive Officer, stated, “Once again we demonstrated our ability to grow revenue and profits during a very difficult macroeconomic backdrop. Our enhanced focus on deliberate underwriting, our conservative approach to balance sheet leverage and our experience in navigating past cycles continues to support our dividend that as of today yields over 12% on a trailing twelve month basis. Our portfolio is designed to produce steady performance in all economic conditions while protecting our capital for future opportunities.” Results of operations for quarter ended September 30,...

HOUSTON, Nov. 13, 2023 (GLOBE NEWSWIRE) — U.S. Energy Corporation (NASDAQ: USEG, “U.S. Energy” or the “Company”), a growth-focused energy company engaged in operating a portfolio of high-quality producing oil and natural gas assets, today reported financial and operating results for the three months ended September 30, 2023. THIRD QUARTER 2023 HIGHLIGHTSNet daily production of 1,652 barrels of oil equivalent per day (“Boe/d”), a 6% decrease over third quarter of 2022 Oil production of 100,071 barrels, or 66% of total production Lease Operating Expense of $4.0 million, or $26.31 per Boe, a 23% and 19% decrease, respectively, from third quarter of 2022 Adjusted EBITDA of $1.6 million during the quarterPRODUCTION UPDATE During the third quarter of 2023, the Company produced 152,013 Boe, or an average of 1,652 Boe/d, a 6% decrease compared...

$2.5 billion global licensing, co-development, and commercialization agreement expands worldwide potential of novel radioenhancer NBTXR3 16.9 months median progression free survival (mPFS) and 23.1 months median overall survival (mOS) following radiotherapy-activated (RT) NBTXR3 in topline Study 102 Phase 1 data in head and neck cancer strengthens hypotheses for pivotal NANORAY-312 trial design Promising initial anti-tumor efficacy, median overall survival (mOS) of 23 months, 92% local disease control rate (DCR), favorable safety profile and recommended dose established for NBTXR3 in locally advanced pancreatic cancer €50.9 in capital from recent financing including second equity tranche from collaboration partner extends cash runway into 2Q 2025 assuming a milestone Successful removal of the EIB cash covenant Multiple clinical readouts...